| Income Statement | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Loss before income taxes | -5,013 | -3,864 | -2,616 | -1,930 |
| Net loss | -5,013 | -3,864 | -2,616 | -1,930 |
| Net loss per share (basic) | -0.55 | -0.45 | -0.4 | -0.6 |
| Net loss per share (diluted) | -0.55 | -0.45 | -0.4 | -0.6 |
| Weighted average number of shares of common stock outstanding (basic) | 9,087,202 | 8,595,288 | 6,615,320 | 3,228,363 |
| Weighted average number of shares of common stock outstanding (diluted) | 9,087,202 | 8,595,288 | 6,615,320 | 3,228,363 |
Vivos Therapeutics, Inc. (VVOS)
Vivos Therapeutics, Inc. (VVOS)